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Abstract
Background: In this retrospective cohort study, we evaluated the drug therapies used for early rheumatoid (RA)
and undifferentiated (UA) arthritis patients.
Methods: From a nationwide register maintained by the Social Insurance Institution, information on sex, date of
birth, and date of special medicine reimbursement decision for all new Finnish RA and UA patients between 2011
and 14 were collected, and their DMARD (Disease Modifying Antirheumatic Drug) purchases during the first year
after the diagnosis were analyzed.
Results: A total of 7338 patients with early RA (67.3% female, 68.1% seropositive) and 2433 with early UA (67.8%
female) were identified. DMARDs were initiated during the first month after the diagnosis to 92.0% of the patients
with seropositive RA, 90.3% with seronegative RA and to 87.7% with UA (p < 0.001). Respectively, 72.1, 63.4, and
42.9% of the patients (p < 0.001) purchased methotrexate; 49.8, 35.9, and 16.0% (p < 0.001) as part of a DMARD
combination during the first month. By the end of the first year after the diagnosis, self-injected biologics were
purchased by 2.6, 5.3 and 3.1% (p < 0.001) of them. Only 1.4, 2.6 and 3.0% (p < 0.001) of the patients were not
receiving any DMARDs. During the first year, 83.4% of the seropositive RA patients had purchased methotrexate,
50.4% sulfasalazine, 72.1% hydroxychloroquine, and 72.6% prednisolone.
Conclusions: Currently, combination therapy including methotrexate is a common treatment strategy for early
seropositive RA in Finland. Despite an easy access to biologics, these drugs are seldom needed during the first year
after diagnosis.
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Background
All modern recommendations of drug therapy for rheuma-
toid arthritis (RA) underline the importance of early treat-
ment aiming at remission and the key role of methotrexate
(MTX). However, the role of the initial use of combinations
of conventional synthetic disease modifying antirheumatic
drugs (csDMARDs) causes dissension [1–3]. In Finland, the
findings of the FIN-RACo and the NEO-RACo trials have
influenced the clinical practice [4–7]. The national Current
Care Guideline from the year 2015 advocates the initiation
of three csDMARDs, the so-called FIN-RACo combination:
MTX, sulfasalazine (SSZ), hydroxychloroquine (HCQ), and
low-dose prednisolone (PRD) in early, active RA [8]. In the
preceding versions in 2003 and 2009, however, the use of
combination therapy was less rigorously recommended
than in the current version.
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Undifferentiated arthritis (UA) is an inflammatory
arthritis where no specific diagnostic criteria are fulfilled.
In Finland there are no specific early arthritis clinics, nor
distinct treatment recommendations for UA, but the ac-
tive treat-to-target (T2T) principle has been followed in
clinical practice [9].
Implementing recommendations in real life may some-
times be suboptimal, but eventually they do bring about im-
provement to the use of DMARDs [10]. The data on the
modern DMARD prescription patterns in early RA is still
scarce, and seldom detailed. In a review article of studies
done in 2002–2013, the penetration of antirheumatic ther-
apy was found to be better in cohorts treated by rheumatol-
ogists (77–98%) than in cohorts allegedly treated by a mix
of physicians (39–63%) [11]. In addition, a patient may not
always use the prescribed medication. In the present study
we describe how Finnish patients with early RA or UA pur-
chased DMARDs between 2011 and 2015.
Methods
Finland’s National Health Insurance covers both Finnish
and foreign citizens residing permanently in Finland. The
costs of most medicines prescribed by a doctor for the treat-
ment of a disease are partially reimbursed by the Social In-
surance Institution (SII) either at basic, lower special, or
higher special rate, depending on the duration and severity
of the disease. Patients with chronic inflammatory rheumatic
disorders can be granted a special reimbursement (SR) (re-
imbursement of 65 to 72% of the drug price) for antirheu-
matic drugs after filling a medical certificate to SII. This
certificate must describe the diagnostic procedures, an
ICD10 diagnosis, and prescribed medication and be written
in a rheumatology clinic. The certificates are reviewed by an
insurance physician of the SII before the special reimburse-
ment is granted after approximately 2–4weeks. At one
transaction, up to 3months’ supply of medicines can be re-
imbursed. Since it is economically very much in the patients’
interest, practically all Finnish patients with anti-rheumatic
medication for chronic inflammatory rheumatic disorders
are entitled to reimbursement, and the pharmacists encour-
age their customers to request it if the reimbursement has
not been applied for. There is also an annual maximum
limit of out-of-pocket costs, which in 2020 is set at EUR
578. If the patients exceed the annual maximum, they can
get an additional reimbursement, which means that for the
rest of the year, they only pay a EUR 2.50 co-payment for
each reimbursable medicine. This is of the greatest import-
ance when the patient is prescribed some of the expensive
medications such as self-injected biologics.
Patient cohort
On grounds of the information in these medical certifi-
cates, SII maintains a nationwide register of the reim-
bursement decisions and the 3-digit ICD10 diagnoses
behind them. From this register we assessed data col-
lected between 1 January 2011 and 31 December 2014,
and collected information on adult (> 16 years old) pa-
tients who, for the first time, had been granted a special
reimbursement of medications for rheumatoid factor
(RF) and/or anti-citrullinated peptide antibody (ACPA)
positive (ICD-10 diagnosis M05) RA, RF and ACPA
negative RA (M06), or UA (M13). The information in-
cluded sex, date of birth, and the date of the reimburse-
ment decision which is the index day in our study.
The SII maintains also a register on the drugs pur-
chased from pharmacies and reimbursed according to
the basic or the special rate. In this register, drugs are
classified according to the Anatomical Therapeutic
Chemical (ATC) code. The register also includes the
amount of the drug and the date of purchase. From this
register, we collected data on the drugs purchased by the
study cohort for 31 days before the index day (to include
medications possibly purchased before the reimburse-
ment decision) and for up to 1 year after the index day.
All csDMARDs, glucocorticoids and self-injected bio-
logics were included in the analysis. The number of
DMARD purchases by the end of the first year after the
index date was evaluated in each diagnosis group, as well
as among the patients who initiated the FIN-RACo com-
bination (with or without PRD) or not. Our study does
not include the small proportion of patients who have
received intravenous biologicals in public hospitals at
their cost, because these medications are not reimbursed
and registered by the SII.
Statistical methods
Statistical comparisons between diagnoses were made by
using the χ2 test. Multivariate analyses were performed
to identify whether age and gender were associated with
the initiation of DMARD therapy (versus no DMARDs)
or with the initiation of combination therapy (versus
monotherapy) within the first month after the index date
in each diagnosis group separately.
Results
Between 2011 and 2014, altogether 9771 adult (> 16
years old) patients with a new inflammatory arthritis
diagnosis were identified, 4998 patients with seropositive
RA [67.0% female, mean (SD) age 58 (15) years]; 2340
with seronegative RA [67.7% female, 56 (17) years]; and
2433 with UA [67.8% female, age 49 (17) years].
The drugs purchased by the patients during the first
month after the index day are presented in Table 1. The
seropositive RA patients used more all, as well as MTX-
based csDMARD-combinations, more MTX and pred-
nisolone than the seronegative RA or UA patients. The
use of any other csDMARDs than MTX, SSZ, or HCQ
was rare during the first months in all patient groups,
Muilu et al. BMC Rheumatology            (2020) 4:34 Page 2 of 8
and only a handful of patients started using self-injected
biological DMARDs (bDMARDs) at this early phase.
As expected, during the first year the proportions of
patients purchasing any csDMARDs increased, espe-
cially in the seropositive RA group (Table 2). MTX,
SSZ, and HCQ remained the absolute most used
drugs, followed by leflunomide (LEF) with approxi-
mately 5% of patients in each group having purchased
it during the first year; all other csDMARDs having a
much smaller share. Self-injected biologics were initi-
ated by 5.3% of the seronegative RA patients, and less
often in the two other patient groups (p < 0.001).
Only 3% of the patients in the UA group had not
purchased any DMARDs during the first year, in the
other groups the proportion of patients with no medi-
cations was even smaller (p < 0.001).
The median numbers (IQR) of patients’ DMARD pur-
chases by the end of the first year after diagnosis are
presented in Table 2. We further divided patients into
two groups depending on whether they were initially
treated with the FIN-RACo combination (MTX + SSZ +
HCQ) or not. In the FIN-RACo group, the median
(IQR) number of DMARD purchases was 18 (15 to 22)
for seropositive RA, 19 (15 to 22) for seronegative RA,
and 18 (15 o 24) for UA during the first year, whereas
the respective numbers in the non-FIN-RACo group
were 10 (6 to 13) for seropositive RA, 9 (6 to 13) for
seronegative RA, and 7 (4 to 11) for UA. Thus, patients
Table 1 Numbers and proportions (%) of patients with seropositive rheumatoid arthritis (RA), seronegative RA and undifferentiated








Females N (%) 3349 (67.0) 1584 (67.7) 1650 (67.8)
Mean age at diagnosis, years (SD) 58 (15) 56 (17) 49 (17)
Combination strategies of DMARDs, N(%)
Two DMARDs 1684 (33.7) 727 (31.1) 395 (16.2) < 0.001
Three DMARDs 1118 (22.4) 255 (10.9) 77 (3.1) < 0.001
MTX-based combination 2489 (49.8) 841 (35.9) 390 (16.0) < 0.001
FIN-RACo combination* 1114 (22.3) 253 (10.8) 75 (3.1) < 0.001
MTX + SSZ + HCQ + PRD 922 (18.4) 205 (8.8) 52 (2.1)
MTX + SSZ + HCQ 192 (3.8) 48 (2.1) 23 (0.9)
Medications
Methotrexate (MTX) 3602 (72.1) 1483 (63.4) 1043 (42.9) < 0.001
MTX per os 3428 (68.6) 1399 (59.8) 949 (39.0)
MTX s.c. 174 (3.5) 84 (3.6) 94 (3.9)
Sulfasalazine (SSZ) 2059 (41.2) 880 (37.6) 1121 (46.1) < 0.001
Hydroxychloroquine (HCQ) 2272 (55.5) 940 (40.2) 472 (19.4) < 0.001
Leflunomide 51 (1.0) 30 (1.3) 23 (1) 0.48
Azathioprine 29 (0.6) 11 (0.5) 14 (0.6) 0.83
Aurathiomalate 9 (0.2) 2 (0.1) 2 (0.1) 0.44
Auranofin 3 (0.1) 1 (0.0) 1 (0.0) 0.95
Cyclosporine 1 (0.0) 3 (0.1) 6 (0.3) 0.015
Prednisolone (PRD) 3025 (60.5) 1352 (57.8) 890 (36.6) < 0.001
Self-injected biologics (all) 41 (0.8) 28 (1.2) 17 (0.7) 0.15
Etanercept 3 (0.06) 11 (0.47) 2 (0.08)
Adalimumab 4 (0.08) 6 (0.27) 1 (0.04)
Certolizumab 1 (0.02) 0 (0) 0 (0)
Golimumab 3 (0.03) 1 (0.04) 0 (0)
Abatacept 1 (0.02) 0 (0) 0 (0)
No antirheumatic medication 401 (8.0) 227 (9.7) 300 (13.3) < 0.001
Only prednisolone 85 (1.7) 63 (2.7) 46 (1.9) 0.61
*FIN-RACo combination: Methotrexate (MTX), sulfasalazine (SSZ), and hydroxychloroquine (HCQ) often combined with low-dose prednisolone (PRD)
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in the FIN-RACo group had almost twice as many
DMARD purchases as the rest of the patients.
In multivariate analyses, using age and gender as co-
variates, we found that gender did not predict whether
DMARDs were initiated or not, or whether the patient
was treated with combination therapy or monotherapy
during the first month after the index date in any of the
three diagnosis groups. Higher age was negatively associ-
ated with DMARD initiation within a month from diag-
nosis among UA patients [OR 0.99 (CI 0.98 to 0.99)] but
not among RA patients. The initiation of combination
therapy decreased with a rising age among seropositive
RA patients [OR 0.99 (CI 0.98 to 0.99)] but not among
other diagnosis groups.
Discussion
In Finland, early arthritis patients are mainly treated by
rheumatologists. The Current Care Guideline advises
general practitioners to refer all patients with suspected
RA to specialist clinics. In addition, a rheumatolo-
gist’s certificate is needed to apply special reimburse-
ment for antirheumatic medication, by which we
identified our cases. Consequently, our cohort in-
cludes those arthritis patients, who had been exam-
ined by rheumatologists and prescribed DMARDs
and glucocorticoids. Obviously, all patients with UA
are not included. These facts explain, why within
one month from the index date more than 90% of
the RA patients purchased DMARDs and nearly 70%
MTX. In seropositive patients, the percentages were
higher, and within one year, only 1.4% of the sero-
positive and 2.6% of the seronegative RA patients
had not purchased any DMARDs. For the UA pa-
tients the DMARD coverage was slightly less. These
numbers also suggest a good drug adherence among
Finnish arthritis patients.
Table 2 Numbers and proportions (%) of patients with seropositive rheumatoid arthritis (RA), seronegative RA and undifferentiated
arthritis having used various anti-rheumatic drugs by the end of the first year after arthritis diagnosis. Also, the number of DMARD








Females N (%) 3349 (67.0) 1584 (67.7) 1650 (67.8)
Mean age at diagnosis, years (SD) 58 (15) 56 (17) 49 (17)
Number of DMARD purchases,
median (IQR)
11 (7, 16) 10 (6, 14) 7 (4, 11) < 0.001
Medications
Methotrexate (MTX) 4167 (83.4) 1789 (76.4) 1512 (62.1) < 0.001
MTX per os 3998 (80.0) 1706 (72.9) 1406 (57.8)
MTX s.c. 625 (12.5) 308 (13.2) 310 (12.7)
Sulfasalazine (SSZ) 2520 (50.4) 1090 (46.6) 1362 (56.0) < 0.001
Hydroxychloroquine (HCQ) 3603 (72.1) 1357 (58.0) 866 (35.6) < 0.001
Leflunomide 256 (5.1) 121 (5.2) 119 (4.9) 0.89
Azathioprine 65 (1.3) 31 (1.3) 23 (0.9) 0.37
Aurathiomalate 42 (0.8) 12 (0.5) 8 (0.3) 0.023
Auranofin 4 (0.1) 2 (0.1) 2 (0.1) 0.99
Cyclosporine 13 (0.3) 10 (0.4) 23 (0.9) < 0.001
Prednisolone (PRD) 3626 (72.6) 1706 (72.9) 1283 (52.7) < 0.001
Self-injected biologics (all) 131 (2.6) 125 (5.3) 76 (3.1) < 0.001
Etanercept 53 (1.1) 55 (2.4) 31 (1.3)
Adalimumab 40 (0.8) 48 (2.1) 29 (1.2)
Certolizumab 23 0.5) 19 (0.8) 12 (0.5)
Golimumab 19 (0.4) 19 (0.8) 9 (0.4)
Abatacept 8 (0.2) 5 (0.2) 1 (0.04)
Tocilizumab 4 (0.1) 1 (0.04) 1 (0.04)
Ustekinumab 0 (0) 0 (0) 1 (0.04)
No antirheumatic medication 71 (1.4) 60 (2.6) 73 (3.0) < 0.001
Only prednisolone 25 (0.5) 30 (1.3) 24 (1.0) < 0.001
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Our results may not be comparable with studies in
other settings. In a Canadian cohort studying the
DMARD treatment of 24,942 early RA patients during
the year following the diagnosis in 1997–2006, only 21%
of patients treated by a general practitioner received any
DMARDs, but 67% of those treated by a rheumatologist
did so [12]. In a Danish cohort of 1516 early RA patients
studying the initiation of MTX between 1996 and 2006,
only 21% of the patients received MTX within 90 days;
though, in 13% of the patients another DMARD had
been initiated [13]. In studies based on large RA cohorts
from US commercial and Medicare claims databases, the
initiation of DMARD treatment within one year after
diagnosis decreased from 63 to 56% between the cohorts
2004–08 and 2009–12 [14, 15]. Another US study based
on claims databases found that over half of the 63,101
RA patients identified did not receive DMARD treat-
ment within 90 days after diagnosis [16]. In a smaller
Canadian cohort of 204 early RA patients in 2003–06,
only 23% were prescribed a DMARD within 3 months
and 47% within 6 months [17]. Also, in a recent Italian
cohort of 1336 RA patients, less than 40% of the patients
had started treatment with MTX within 3–6 months
from the diagnosis [18].
Better coverages are found in contemporary materials
treated by rheumatologists. In the French ESPOIR co-
hort of 775 early inflammatory arthritis patients, 77% re-
ceived at least one DMARD after a median of four
months [19]. A Canadian study of 339 RA patients
found that 92% of the patients began DMARD therapy
within three months [20]. In a multicenter ERAN cohort
in UK and Eire, DMARDs were prescribed to 97% of the
808 early RA patients; however, the median time of
DMARD initiation was 8 months after the symptom on-
set [21]. An Italian study reported that 83% of 10,401 pa-
tients were prescribed a csDMARD at RA diagnosis but
only 6% of them received combination therapy [22].
Our previous analysis of Finnish early RA patients be-
tween 2000 and 2007 showed that although at the begin-
ning of the study period SSZ was the most commonly
prescribed DMARD during the first 3 months after the
diagnosis, at the end of the observation period (2006–
07) it had given way to MTX (69%) and combination
DMARDs (53%) as the initial treatment [23]. Our earlier
results also demonstrated that the proportion of patients
starting triple combination within the first month in-
creased from 6 to 16% between 2000 and 07. Our
current results confirm that there has been a further in-
crease. However, only 22% of early seropositive RA pa-
tients commenced the triple therapy recommended in
the latest 2015 Current Care Guideline [8]. The Finnish
recommendations from 2009 favored the start of the
triple therapy and low dose prednisolone only for pa-
tients with very active RA, but not automatically as the
first choice in all patients. Also, real life patients diag-
nosed with RA have seldom as active disease as patients
in clinical trials [24], and further, they may have comor-
bidities and polypharmacy contraindicating certain med-
ications, thus it is possible that rheumatologists base
their decisions more on T2T principle than on slavishly
following certain recommendations [25]. Either way,
since we are lacking data of the levels of activity of the
patients’ disease, further conclusions on whether only
one-fifth of the patients had active disease requiring
triple therapy cannot be drawn.
There is a distinction between guidelines encouraging
a T2T strategy on the one hand and what actually hap-
pens in practice. In an ESPOIR cohort, where adherence
to three of the EULAR recommendations concerning the
start and early adjustment of DMARDs was studied, the
adherence rate for all three recommendations was only
23% among early arthritis patients [26]. Still, among
those patients whose treatment adhered to given recom-
mendations, the risk of clinical and radiographic pro-
gression was lower. Knowing that the fulfilment of
treatment guidelines in real life is always suboptimal, the
strict national treatment recommendations, such as the
recommendation of triple therapy initiation in early RA
in Finland, will probably lead to optimal outcomes.
The number of DMARD purchases could reflect drug
adherence although some patients may not always buy
medication for the next three months as usually hap-
pens. In our analysis, the patients initiating the FIN-
RACo combination had twice the number of DMARD
purchases during the first year compared to those pa-
tients who did not start with the FIN-RACo combin-
ation. Frequent purchases suggest a regular drug usage
and good survival rate of the FIN-RACo combination.
Two Finnish studies based on real life early arthritis
patient cohorts have been published. The first one in-
cluded 406 early RA or UA patients between 2008 and
11 [27]. Of the RA patients, at three months 20% were
using triple therapy, 33% other MTX based combination,
36% MTX monotherapy, and 8% other DMARD mono-
therapy; for the UA patients the respective percentages
were 6, 28, 43, and 17%, respectively. At one year, the
proportions of RA patients using various medications
had not changed markedly. In a more recent (2011–14)
FIN-ERA cohort of 611 DMARD naïve early arthritis pa-
tients (506 RA and 105 UA patients) recruited in five
Finnish outpatient rheumatology clinics, MTX-based
combination therapy was initiated to 68% of the patients
and the proportion of triple combination (MTX, SSZ
and HCQ) was 31% [28]. These results, in line with our
results, show that DMARD initiation for early arthritis
patients is generally comprehensive in Finland.
In Finland there are no separate treatment recommen-
dations for UA, but the active T2T principle is widely
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used in clinical practice regardless of the diagnosis. The
European League of EULAR recommendations for early
arthritis in 2007 recommended for patients at risk of de-
veloping persistent and/or erosive arthritis a DMARD as
early as possible, preferably MTX, even if no classifica-
tion criteria for a specific disease are fulfilled [29]. The
latest update of the recommendation in 2016 presented
no major changes to these principles [9]. The fulfillment
of the EULAR recommendations for the treatment of
early arthritis was studied in 813 patients from the
ESPOIR cohort between 2002 and 05; 78% of patients
started a DMARD, 67% MTX and 52% reached remis-
sion [30]. In our material the DMARD initiation was
more comprehensive, but the proportion on MTX lower;
this might be explained by the fact that traditionally SSZ
has been prescribed in seronegative oligoarthritis in
Finland.
In our study, the use of self-injected biological
DMARDs was more common among seronegative RA
patients than seropositive RA or UA patients. Seronega-
tive RA may be a heterogenous group of diseases, as
shown in a recent 10-year observational study [31], thus
explaining poorer treatment outcomes with csDMARDs
and a greater need for switching to bDMARDs.
A shortcoming of this study is the lack of clinical data;
we do not have information of the disease’s activity at
diagnosis, nor at follow-up. Further, we may miss pa-
tients that the physician intends not to treat. Neverthe-
less, the incidence of seropositive RA has remained
stable throughout this millennium, that of seronegative
RA has decreased slightly supposedly due to changed
diagnostics, and for the same reason, the incidence of
UA has increased [32]. Thus, it seems unlikely that we
are missing many patients. However, since this is a
register-based study and we lack the data on the dur-
ation of symptoms before the diagnosis, it is possible
that the current study includes some patients that are di-
agnosed with a time lag; in these cases, DMARDs used
represent patients’ initial treatment rather than the treat-
ment of early rheumatic disease. Also, we do not know
how high a proportion of UA patients received a more
specific diagnosis later; this could offer an interesting
area for further research. Further, in the lack of clinical
data it is possible that a certain proportion of the UA
patients in our study may not be comparable to patients
in so called early arthritis clinics, but have a chronic in-
flammatory arthritis requiring specific anti-rheumatic
drug therapy.
Even though we do not have any clinical outcome
measures, the initiation of self-injected biologics served
as a surrogate marker of treatment failure. We were
expecting to see that patients having received combin-
ation DMARDs as their first treatment, and thus judged
by their treating rheumatologist to have an active disease
to be the ones to end up starting a biologic earlier and
more often than other patients, but at least during the
first year that was not the case. Thus, at least in the early
phase, combination DMARD treatment appears to be
effective.
Although we are lacking the data on infusion based
biological drugs, only a small proportion of patients are
initiating them during the first year after the diagnosis,
the time period of interest in our study. According to
the Finnish ROB-FIN register study, in 2004–14 the first
TNF-inhibitors were initiated to RA patients after a me-
dian (IQR) of 8.2 (2.4–17) years of disease duration,
most often with adalimumab (39%) or etanercept (39%),
while infliximab was a rarer choice (12%) [33]. Accord-
ing to the most recent, yet unpublished, ROB-FIN regis-
ter data from 2010 to 15, the use of infliximab as the
first biologic had decreased from 7.5 to 4.2% for RA pa-
tients (Kalle Aaltonen, personal communication). Rituxi-
mab was the first choice for as many as 20–23% of the
RA patients. Still, the majority started self-injected drugs,
and the median (IQR) point of starting the first biologic
was after 10 (4.4–18) years of disease duration. Conse-
quently, our results of the first year treatment would
hardly have changed markedly, were the infusion-based
drugs included.
Conclusions
In this study we wanted to describe the drug therapies used
for early rheumatoid (RA) and undifferentiated (UA) arth-
ritis patients between 2011 and 2015. The rheumatologist-
based treatment received by the Finnish new-onset arthritis
patients is early initiation of cDMARDs, mainly MTX, and
often in combinations.
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